24/7 Market News Snapshot 23 May, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

May 23, 2025

DENVER, Colo., 23 May, 2025 (www.247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
Imunon, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology firm specializing in immunotherapy for advanced ovarian cancer, is experiencing significant investor interest, as reflected by its pre-market stock price surge of 31.41%, climbing to $0.546 with a trading volume of approximately 16.28 million shares. This positive market activity coincides with the release of promising results from their Phase 2 OVATION 2 Study concerning IMNN-001, a novel therapy aimed at improving outcomes for patients battling this challenging disease.

The Phase 2 study results revealed substantial advancements in both overall and progression-free survival rates for the 112 women treated with IMNN-001 in combination with standard chemotherapy. Notably, participants receiving IMNN-001 exhibited a median overall survival increase of 13 months compared to traditional therapies. Some subgroups, particularly those treated with IMNN-001 alongside PARP inhibitors, demonstrated even more remarkable outcomes, with median overall survival not yet reached after five years of follow-up.

Dr. Stacy Lindborg, the president and CEO of Imunon, expressed optimism regarding the study outcomes, emphasizing the transformative potential of IMNN-001 for women facing advanced ovarian cancer. As part of its commitment to advancing treatment options, the company has initiated the pivotal Phase 3 OVATION 3 Study, following consultations with the U.S. Food and Drug Administration (FDA). This study aims to further evaluate the efficacy of IMNN-001 among newly diagnosed patients, focusing on improving overall survival while also exploring additional endpoints.

The encouraging findings will be showcased at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting and are set to be published in Gynecologic Oncology, marking a critical advancement in the pursuit of innovative therapies to better serve patients with ovarian cancer. As Imunon continues to progress its clinical development efforts, it remains dedicated to enhancing treatment landscapes and improving patient outcomes.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.